Ceftriaxone TX 32 US S30, Ref 412302 and Ceftriaxone TX 32 US F100, Ref 507058 ETEST is a qu...
FDA Device Recall #Z-2126-2017 — Class II — January 1, 2017
Recall Summary
| Recall Number | Z-2126-2017 |
| Classification | Class II — Moderate risk |
| Date Initiated | January 1, 2017 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | BioMerieux SA |
| Location | Marcy L'Etoile |
| Product Type | Devices |
| Quantity | 4656 kits |
Product Description
Ceftriaxone TX 32 US S30, Ref 412302 and Ceftriaxone TX 32 US F100, Ref 507058 ETEST is a quantitative technique for determining the antimicrobial susceptibility of Gram-negative and Gram-positive aerobic ba
Reason for Recall
Potential performance issue on strain categorization.
Distribution Pattern
USA (nationwide) Distribution to the states of : AZ, AR, CA, CT, DE, FL, GA, HI, IL, LA, ME, MA, MI, MN, MO, MT, NH, NY, NC, OR, PA, SC, SD, TN, TX, WA
Lot / Code Information
Ref 412302 1002939460, 1003361690, 1003848910, 1004041770, 1004394530, 1004731200, 1004876830, 1005327130; Ref 507058 1002940890, 1003128150, 1003361950, 1003849820, 1004041790, 1004239890, 1004395510, 1004525370, 1004756050, 1004828430, 1004876860, 1004919030
Other Recalls from BioMerieux SA
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-0084-2022 | Class II | MYLA Versions: 4.7, 4.7.1, 4.8, 4.8.1 and 4.8.2... | Sep 2, 2021 |
| Z-2225-2021 | Class II | MYLA software. Used to manage microbiology tes... | Jun 22, 2021 |
| Z-0218-2019 | Class II | NucliSENS¿ Magnetic Extraction Reagents | Sep 17, 2018 |
| Z-2331-2018 | Class II | VIDAS FSH, Ref 30407-01, IVD, Rx. The firm nam... | Apr 9, 2018 |
| Z-2169-2018 | Class II | VIDAS TOXO IgG Avidity is an automated qualitat... | Mar 23, 2018 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.